NCT00481767 - Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age. | Biotech Hunter

Enrollment

676

Participants

Timeline

Start Date

October 1, 2007

Primary Completion Date

February 25, 2010

Study Completion Date

July 26, 2010

Conditions

Human Papillomavirus (HPV) Infection

Interventions

BIOLOGICAL

Cervarix

The vaccine was administered according to a 0, 1, and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.

DRUG

Placebo Al(OH)3

Placebo was administered according to a 0, 1 and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.

Trial Locations (2)

GSK Investigational Site, Dakar

GSK Investigational Site, Mwanza